---
title: "Protalix BioTherapeutics, Inc. (PLX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PLX.US.md"
symbol: "PLX.US"
name: "Protalix BioTherapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T18:19:14.119Z"
locales:
  - [en](https://longbridge.com/en/quote/PLX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PLX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PLX.US.md)
---

# Protalix BioTherapeutics, Inc. (PLX.US)

## Company Overview

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.protalix.com](https://www.protalix.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: B (0.22)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 48 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 27.80% |  |
| Net Profit YoY | 292.32% |  |
| P/B Ratio | 2.28 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 153086119.80 |  |
| Revenue | 76381000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 27.27% | A |
| Profit Margin | 20.07% | A |
| Gross Margin | 87.77% | A |
| Revenue YoY | 27.80% | A |
| Net Profit YoY | 292.32% | A |
| Total Assets YoY | 38.49% | A |
| Net Assets YoY | 48.71% | A |
| Cash Flow Margin | 98.42% | C |
| OCF YoY | 27.80% | A |
| Turnover | 0.87 | B |
| Gearing Ratio | 34.31% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Protalix BioTherapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "27.80%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "292.32%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.28",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "153086119.80",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "76381000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "27.27%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "20.07%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "87.77%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "27.80%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "292.32%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "38.49%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "48.71%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "98.42%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "27.80%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.87",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "34.31%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 9.98 | 24/386 | 32.59 | 29.82 | 25.94 |
| PB | 2.28 | 210/386 | 3.79 | 3.01 | 2.64 |
| PS (TTM) | 2.00 | 51/386 | 3.30 | 2.44 | 2.05 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-14T04:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 50% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.00 |
| Highest Target | 12.00 |
| Lowest Target | 10.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/PLX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/PLX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/PLX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/PLX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**